Post-Chemo PET Scan Results Indicative of Outcomes in Hodgkin Lymphoma

Share this content:

the Cancer Therapy Advisor take:

Post-chemotherapy positron emission tomography (PET) can help guide radiotherapy in Hodgkin lymphoma, according authors of a recent study published in the Journal of Clinical Oncology. The researchers analyzed 739 patients with advanced Hodgkin lymphoma with residues of at least 2.5 cm after chemotherapy. Of all patients included in the analysis, 74% had PET-negative residues and did not receive additional radiotherapy. Four-year progression-free survival (PFS) was 91.5%. In contrast, 4-year PFS was 86.1% for the 26% of PET-positive patients who received additional radiotherapy. Data from an analysis of a subset of PET-positive patients with a relative reduction of less than 40%, risk for progression or relapse within the first year was 23.1% versus those who experienced larger reductions. These results prompted the researchers to conclude that patients with PET-positive disease after chemotherapy and poor tumor shrinkage are more likely to experience progression or relapse.

Nivolumab Designated Breakthrough Therapy for Hodgkin Lymphoma
Post-Chemo PET Scan Results Indicative of Outcomes in Hodgkin Lymphoma

Patients with Hodgkin lymphoma who have PET-positive residual disease after chemotherapy and poor tumor shrinkage are at high risk of progression or relapse.

READ FULL ARTICLE From Ascopubs

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs